Intensive cholesterol-lowering intervention and anti-tumor immunity modeled in prostate cancer
以前列腺癌为模型的强化降胆固醇干预和抗肿瘤免疫
基本信息
- 批准号:10802975
- 负责人:
- 金额:$ 69.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-21 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:AftercareAnimal ModelAnimalsApoptosisAtherosclerosisBiologicalBiological MarkersBiopsyBloodCD8-Positive T-LymphocytesCD8B1 geneCancer ControlCancer PatientCancer cell lineCardiac healthCell physiologyCellsCessation of lifeChemopreventionCholesterolClinical ResearchClinical TrialsColon CarcinomaCombined Modality TherapyDataDendritic CellsDiagnosisDisease ProgressionDrug CostsEnrollmentErectile dysfunctionExperimental ModelsExposure toFRAP1 geneFutureGeneticGenetic studyGoalsHeat shock proteinsHepaticHigh-Risk CancerHumanImmuneImmune responseImmune systemImmunologic MemoryImmunologic StimulationImmunologicsIn VitroIncontinenceInfiltrationInterventionKnockout MiceLow-Density LipoproteinsLymphocyteLymphocytic InfiltrateMacrophageMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMeasuresMemoryMeta-AnalysisModelingMonitorMulti-Institutional Clinical TrialMusNeoplasm MetastasisNewly DiagnosedOperative Surgical ProceduresOutcomeParticipantPathway interactionsPatientsPeripheralPharmaceutical PreparationsPhasePhase III Clinical TrialsPopulationPopulation StudyPre-Clinical ModelPrevention strategyPrimary Cancer PreventionProliferatingProstateProstatectomyRadiationRegulatory T-LymphocyteReportingResourcesRiskSecondary Cancer PreventionSecondary PreventionSerumSignal TransductionSimvastatinSolidT memory cellTestingTissuesTumor ImmunityTumor Tissueadaptive immune responseanti-tumor immune responseantitumor effectcancer typedesignepidemiology studyezetimibehigh risk menimmunogenic cell deathimmunogenicityimmunoregulationimproved outcomein vivoindividual patientmTOR Signaling PathwaymTOR inhibitionmalignant breast neoplasmmenmortality riskmouse modelneutrophilpatient responsepatient subsetspharmacologicphase changepreclinical studypreventprimary endpointprospectiveprostate biopsyprostate cancer modelprostate cancer progressionprostate cancer riskrational designresponsetraffickingtrial designtumortumor growthtumor progression
项目摘要
PROJECT SUMMARY
In epidemiologic studies, a strong association has been noted between cholesterol-lowering therapy with statins
and lower risk of death from prostate cancer. Animal studies suggest that cholesterol-lowering can decrease
the progression of prostate cancer. The biologic effects of lowering-cholesterol in prostate cancer patients are
not fully understood. It is very likely that lowering cholesterol can directly inhibit the growth of the tumor and its
potential to metastasize. However, our preliminary data suggest another important mechanism: cholesterol-
lowering enhances an antitumor immune response. In our animal models, cholesterol-lowering reduced
signaling through the mTOR pathway in immune cells. We show that this same signaling change is seen in
prostate cancer patients when their blood cholesterol is lowered. Our preliminary data also suggest that
cholesterol-lowering enhances immune memory cells that are critical for long-term cancer control. Our working
hypothesis is that lowering serum cholesterol (1) decreases TORC2 signaling in lymphocytes and enhances
formation of central memory CD8+ T cell, (2) can be optimized by controlling Tregs, and (3) directly increases
tumor immunogenicity. To test this hypothesis and to relate findings from our mouse models, we propose parallel
mouse and human clinical studies. Therefore, Aim 1 evaluates the effects of cholesterol-lowering on CD8+
memory cells as well as other critical components of the adaptive immune response, such as regulatory T cells.
Our preliminary data show that cholesterol-lowering makes the tumor more “visible” to the immune system by
increasing the expression of heat shock proteins. We evaluate the effects of cholesterol-lowering on the tumor
itself, which may then alter the immune response. We also assess the effects of tumor, exposed to cholesterol-
lowering, on dendritic cells, macrophages and neutrophils. Aim 2 evaluates cholesterol-lowering in a prospective
clinical trial in men with low and intermediate-risk prostate cancer being managed with active surveillance. These
men are at high risk for cancer progression and needing radical surgery or radiation, which often leaves men
with permanent incontinence and erectile dysfunction. In the proposed trial, men with newly diagnosed prostate
cancer will undergo maximal cholesterol-lowering or standard management. The prostate biopsy tissue before
and after starting treatment will be compared to determine if cholesterol lowering increases CD8+ T cells in the
tumor, which are required for an antitumor immune response. We will also examine immune cells in the blood
to identify and enrich for patient subgroups most likely to respond. A positive study will provide a strong rationale
for a phase 3, multicenter clinical trial to determine if cholesterol-lowering can prevent the formation or
progression of prostate cancer. It will also provide an immune mechanism that can potentially improve outcomes
in other cancers beyond prostate cancer.
项目摘要
在流行病学研究中,他汀类药物与降胆固醇治疗之间有很强的相关性
以及降低前列腺癌死亡风险。动物研究表明,降低胆固醇可以减少
前列腺癌的发展降低前列腺癌患者胆固醇的生物效应是
没有完全理解。很可能降低胆固醇可以直接抑制肿瘤的生长,
转移的可能性然而,我们的初步数据表明另一个重要的机制:胆固醇-
降低可增强抗肿瘤免疫应答。在我们的动物模型中,
通过免疫细胞中的mTOR通路进行信号传导。我们发现,同样的信号变化也出现在
前列腺癌患者血液胆固醇降低时。我们的初步数据还表明,
降低胆固醇可增强对长期癌症控制至关重要的免疫记忆细胞。我们的工作
假设降低血清胆固醇(1)会降低淋巴细胞中的TORC 2信号传导,
中枢记忆性CD 8 + T细胞的形成,(2)可以通过控制TcB来优化,以及(3)直接增加
肿瘤免疫原性为了测试这一假设并将我们的小鼠模型的发现联系起来,我们提出了平行的
小鼠和人类临床研究。因此,目的1评价了降低胆固醇对CD 8 + T细胞的影响。
记忆细胞以及适应性免疫应答的其他关键成分,如调节性T细胞。
我们的初步数据表明,降低胆固醇使肿瘤更“可见”的免疫系统,
增加热休克蛋白的表达。我们评估降低胆固醇对肿瘤的影响
这可能会改变免疫反应。我们还评估了肿瘤的影响,暴露在胆固醇中-
降低树突状细胞、巨噬细胞和中性粒细胞。目的2在一项前瞻性研究中评价胆固醇降低
在低风险和中等风险前列腺癌男性中进行的临床试验,通过积极监测进行管理。这些
男性癌症进展的风险很高,需要根治性手术或放射治疗,这往往使男性
患有永久性尿失禁和勃起功能障碍在拟议的试验中,新诊断的前列腺患者
癌症将经历最大的胆固醇降低或标准处理。前列腺活检组织
并在开始治疗后进行比较,以确定胆固醇降低是否增加了CD 8 + T细胞。
肿瘤,这是抗肿瘤免疫反应所需的。我们还将检查血液中的免疫细胞
以识别和丰富最有可能应答的患者亚组。一项积极的研究将提供有力的理由
一项3期多中心临床试验,以确定降低胆固醇是否可以防止形成或
前列腺癌的发展它还将提供一种免疫机制,可以潜在地改善结果
前列腺癌以外的其他癌症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HYUNG L KIM其他文献
HYUNG L KIM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HYUNG L KIM', 18)}}的其他基金
High resolution volumetric MRI for prostate cancer active surveillance
高分辨率体积 MRI 用于前列腺癌主动监测
- 批准号:
9919515 - 财政年份:2017
- 资助金额:
$ 69.2万 - 项目类别:
Qualifying Multi-Transcript Signatures for Active Surveillance of Prostate Cancer
用于前列腺癌主动监测的合格多转录本签名
- 批准号:
8762344 - 财政年份:2014
- 资助金额:
$ 69.2万 - 项目类别:
Qualifying Multi-Transcript Signatures for Active Surveillance of Prostate Cancer
用于前列腺癌主动监测的合格多转录本签名
- 批准号:
8920108 - 财政年份:2014
- 资助金额:
$ 69.2万 - 项目类别:
Qualifying Multi-Transcript Signatures for Active Surveillance of Prostate Cancer
用于前列腺癌主动监测的合格多转录本签名
- 批准号:
9307744 - 财政年份:2014
- 资助金额:
$ 69.2万 - 项目类别:
Heat Shock Protein Vaccine Targeting Carbonic Anhydrase IX in Renal Cell Carcinom
针对肾细胞癌中碳酸酐酶 IX 的热休克蛋白疫苗
- 批准号:
8045311 - 财政年份:2010
- 资助金额:
$ 69.2万 - 项目类别:
Expression profiling of renal cell carcinoma utilizing tissue from CALGB 90206
利用 CALGB 90206 组织进行肾细胞癌的表达谱分析
- 批准号:
8117306 - 财政年份:2008
- 资助金额:
$ 69.2万 - 项目类别:
Expression profiling of renal cell carcinoma utilizing tissue from CALGB 90206
利用 CALGB 90206 组织进行肾细胞癌的表达谱分析
- 批准号:
7649240 - 财政年份:2008
- 资助金额:
$ 69.2万 - 项目类别:
Expression profiling of renal cell carcinoma utilizing tissue from CALGB 90206
利用 CALGB 90206 组织进行肾细胞癌的表达谱分析
- 批准号:
7851081 - 财政年份:2008
- 资助金额:
$ 69.2万 - 项目类别:
Expression profiling of renal cell carcinoma utilizing tissue from CALGB 90206
利用 CALGB 90206 组织进行肾细胞癌的表达谱分析
- 批准号:
8312591 - 财政年份:2008
- 资助金额:
$ 69.2万 - 项目类别:
Expression profiling of renal cell carcinoma utilizing tissue from CALGB 90206
利用 CALGB 90206 组织进行肾细胞癌的表达谱分析
- 批准号:
8013281 - 财政年份:2008
- 资助金额:
$ 69.2万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 69.2万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 69.2万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 69.2万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 69.2万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 69.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 69.2万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 69.2万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 69.2万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 69.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 69.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists